BILIARY CANNULATION VIA THE ENDOSONOGRAPHICALLY CREATED ROUTE DURING REINTERVENTION AFTER EUS-HGS

Haruo Miwa(Yokohama City University Medical Center), Yugo Ishino(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Hiromi Tsuchiya(Yokohama City University Medical Center), Kazuki Endo(Yokohama City University Medical Center), Ritsuko Oishi(Yokohama City University Medical Center), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Shotaro Tsunoda, Yuichi Suzuki(Yokohama City University Medical Center)
Gastrointestinal Endoscopy
May 1, 2025
10.1016/j.gie.2025.03.733
Cited by 0

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
|Journal of Gastroenterology|2017|91
Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with Lenvatinib
|Liver Cancer|2019|91
Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
|Hepatology Research|2011|77